Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
13 déc. 2021 08h00 HE
|
Oncternal Therapeutics
Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021Objective response rate...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2021 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
15 nov. 2021 08h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
09 nov. 2021 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Oncternal Therapeutics
Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interactions with the US FDA on potential registration...
Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
03 nov. 2021 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
02 nov. 2021 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 nov. 2021 16h05 HE
|
Oncternal Therapeutics
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
29 oct. 2021 08h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
05 oct. 2021 16h05 HE
|
Oncternal Therapeutics
Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice...